19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
14
Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization.
University of Nantes
18
Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
The Second People'S Hospital of Fujian Provinc
8
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
University of California San Francisco
53
Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody.
Hangzhou Medical College
5
Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with
Peking University
10
Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes.
Roche Innovation Center Shanghai
49
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.
China Pharmaceutical University
10
Dual Inhibition of IL-2-Inducible T-Cell Kinase (ITK) and Tropomyosin Receptor Kinase A (TRKA) as Potential Treatment for Atopic Dermatitis and Other Inflammatory and Autoimmune Diseases.
Therachem Research Medilab
1
Enhancing the Pharmacokinetic Profile of Interleukin 2 through Site-Specific Conjugation to a Selective Small-Molecule Transthyretin Ligand.
University of The Pacific
21
Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-
Lupin
23
Identification and Validation of New Interleukin-2 Ligands Using DNA-Encoded Libraries.
Philochem
25
Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein.
University of Nantes
4
The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
Sandoz Pharma
26
JAK inhibitors containing a 4-membered heterocyclic amide
Theravance Biopharma R&D Ip